Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial

Many patients with venous thromboembolism (VTE) are elderly, have multiple comorbidities and take several concomitant medications. Physicians may prefer warfarin over direct oral anticoagulants (DOACs) in such patients because comparative data are lacking. This analysis was designed to determine the...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis research 2018-02, Vol.162, p.7-14
Main Authors: Vanassche, Thomas, Verhamme, Peter, Wells, Philip S., Segers, Annelise, Ageno, Walter, Brekelmans, Marjolein P.A., Chen, Cathy Z., Cohen, Alexander T., Grosso, Michael A., Medina, Andria P., Mercuri, Michele F., Winters, Shannon M., Zhang, George, Weitz, Jeffrey I., Raskob, Gary E., Büller, Harry R.
Format: Article
Language:English
Subjects:
Comorbidities
Direct oral anticoagulants
Edoxaban, elderly, polypharmacy, venous
Thromboembolism, vitamin K antagonists
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many patients with venous thromboembolism (VTE) are elderly, have multiple comorbidities and take several concomitant medications. Physicians may prefer warfarin over direct oral anticoagulants (DOACs) in such patients because comparative data are lacking. This analysis was designed to determine the effects of advanced age, comorbidities, and polypharmacy on the efficacy and safety of edoxaban and warfarin in patients with VTE. Using data from the Hokusai-VTE study, we report rates of recurrent VTE and of clinically relevant bleeding by age category (
ISSN:0049-3848
1879-2472
DOI:10.1016/j.thromres.2017.12.005